Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bellicum Pharmaceuticals
Subjects enrolled on the BP-004 study who have completed or discontinued from the study, and are beyond Day 180 will be requested to enroll on this long-term follow up protocol. Long term follow up for gene therapy clinical and safety endpoints will continue up to 15 years.
Age
0–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed written informed consent by the patient or the patient's guardian for children who are minors
Enrolled on BP-004 protocol, received BPX-501 infusion, completed or discontinued from the study, and are beyond Day +180.
You may not be if
Lack of parents'/guardian's informed consent for children who are minors
Loss of allograft prior to 6 months
Clareo Health | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
